FDA issues Complete Response Letter for manganese chloride tetrahydrate (Orviglance), an oral liver MRI contrast agent for renal-impaired patients.
July 2026 Brief
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA OKs ProstACT Trial Part 2 Protocol for Metastatic Prostate Cancer
2
Botensilimab Plus Balstilimab Yields 33% OS Rate at 3 years in MSS mCRC
3
Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
4
The Growing Rationale for Earlier Targeting of GPRC5D in Multiple Myeloma
5